The authors reply

New England Journal of Medicine

Volumn 371, Issue 10, 2014, Pages 966-

  Molina, Israel ^a   Salvador, Fernando ^a   Sánchez Montalvá, Adrián ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BENZNIDAZOLE; GLUCOCORTICOID; POSACONAZOLE;

CARDIOMYOPATHY; CHAGAS DISEASE; CHRONIC DISEASE; CONSENSUS DEVELOPMENT; DRUG TREATMENT FAILURE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; LETTER; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; TRYPANOSOMA CRUZI;

EID: 84908243929     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1407914     Document Type: Letter

References (4)

1. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007;298:2171-81.
2. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006;144:724-34.
3. Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther 2009;7:157-63.
4. Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz 2011;106:641-5.